DE69426835T2 - Derivate von 2-arylalkenyl-azacyclo alkan als sigma rezeptor-liganden, verfahren zu ihrer herstellung und ihrer therapeutischer anwendung - Google Patents

Derivate von 2-arylalkenyl-azacyclo alkan als sigma rezeptor-liganden, verfahren zu ihrer herstellung und ihrer therapeutischer anwendung

Info

Publication number
DE69426835T2
DE69426835T2 DE69426835T DE69426835T DE69426835T2 DE 69426835 T2 DE69426835 T2 DE 69426835T2 DE 69426835 T DE69426835 T DE 69426835T DE 69426835 T DE69426835 T DE 69426835T DE 69426835 T2 DE69426835 T2 DE 69426835T2
Authority
DE
Germany
Prior art keywords
azacyclo
alkan
arylalkenyl
derivatives
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69426835T
Other languages
English (en)
Other versions
DE69426835D1 (de
Inventor
Pierre Calvet
Henry Jacobelli
Jean-Louis Junien
Pierre Riviere
Joseph Roman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Holding France SCA
Original Assignee
Parke Davis and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parke Davis and Co filed Critical Parke Davis and Co
Application granted granted Critical
Publication of DE69426835D1 publication Critical patent/DE69426835D1/de
Publication of DE69426835T2 publication Critical patent/DE69426835T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DE69426835T 1993-12-09 1994-12-09 Derivate von 2-arylalkenyl-azacyclo alkan als sigma rezeptor-liganden, verfahren zu ihrer herstellung und ihrer therapeutischer anwendung Expired - Fee Related DE69426835T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9314814A FR2713639B1 (fr) 1993-12-09 1993-12-09 Nouveaux dérivés de 2-arylalkényl-azacycloalkanes ligands aux récepteurs sigma, leur procédé de préparation et leur application en thérapeutique.
PCT/FR1994/001439 WO1995015948A1 (fr) 1993-12-09 1994-12-09 Nouveaux derives de 2-arylalkenyl-azacycloalkanes ligands aux recepteurs sigma, leur procede de preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
DE69426835D1 DE69426835D1 (de) 2001-04-12
DE69426835T2 true DE69426835T2 (de) 2001-08-16

Family

ID=9453762

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69426835T Expired - Fee Related DE69426835T2 (de) 1993-12-09 1994-12-09 Derivate von 2-arylalkenyl-azacyclo alkan als sigma rezeptor-liganden, verfahren zu ihrer herstellung und ihrer therapeutischer anwendung

Country Status (9)

Country Link
US (2) US5849760A (de)
EP (2) EP0734379B1 (de)
JP (1) JP3594310B2 (de)
AU (1) AU1245495A (de)
CA (1) CA2177739A1 (de)
DE (1) DE69426835T2 (de)
ES (1) ES2157315T3 (de)
FR (1) FR2713639B1 (de)
WO (1) WO1995015948A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751645B1 (fr) * 1996-07-29 1998-12-24 Sanofi Sa Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales
FR2760455B1 (fr) * 1997-03-05 1999-04-16 Jouveinal Inst Rech (-)e-2-(3,4-dichloro-cinnamyl)-1-cyclopropylmethyl- piperidine, son utilite antidiarrheique
EP1138327A1 (de) * 2000-03-29 2001-10-04 Warner-Lambert Company Verwendung von 2-(Arylalkenyl)Azacycloalkan derivativen zur Behandlung von Magen-Darmstörungen, die durch Stress verursacht sind
GB0007842D0 (en) * 2000-03-31 2000-05-17 Spruce Barbara Sigma receptor ligands and their medical uses
AU2002332659A1 (en) * 2001-08-21 2003-03-03 Sepracor, Inc. 2-substituted piperidines that are ligands for monoamine receptors and transporters
FR2833945B1 (fr) * 2001-12-21 2004-03-12 Warner Lambert Co N-cyclopropylmethyl-azacycloalcanes, compositions les contenant et procedes de preparation
DE60318306T2 (de) 2002-03-29 2008-12-11 Eisai R&D Management Co., Ltd. (1-indanon)-(1,2,3,6-tetrahydropyridin)derivat
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
EP1942879A1 (de) 2005-10-31 2008-07-16 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AU2008310201A1 (en) 2007-10-13 2009-04-16 Shenzhen New Electric Science And Technology Co., Ltd Multimedia acoustics system having audio frequency digital interface
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
IL300858A (en) 2020-09-17 2023-04-01 Meletios Therapeutics Compounds for the treatment of viral infection

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2636625B1 (fr) * 1988-09-01 1990-11-09 Jouveinal Sa Benzylamines disubstituees, leur procede de preparation, leur utilisation comme medicament et leurs intermediaires de synthese
US5109002A (en) * 1989-09-08 1992-04-28 Du Pont Merck Pharmaceutical Company Antipsychotic 1-cycloalkylpiperidines
WO1991006297A1 (en) * 1989-10-27 1991-05-16 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
JPH05503517A (ja) * 1989-12-18 1993-06-10 バージニア・コモンウェルス・ユニバーシティ シグマレセプターリガンド及びその用途
IE66180B1 (en) * 1990-02-26 1995-12-13 Jouveinal Sa N-Cycloalkylalkylamines their process of preparation their use as a medicament and their synthesis intermediates
US5231099A (en) * 1991-04-15 1993-07-27 Du Pont Merck Pharmaceutical Company Use of sigma receptor antagonists to enhance the effects of antipsychotic drugs
GB9113031D0 (en) * 1991-06-17 1991-08-07 Smithkline Beecham Plc Compounds
WO1993009094A1 (en) * 1991-10-30 1993-05-13 The Du Pont Merck Pharmaceutical Company Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents
JPH07503461A (ja) * 1992-01-28 1995-04-13 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー カルシウムチャンネル拮抗薬としての化合物
GB9202238D0 (en) * 1992-02-03 1992-03-18 Wellcome Found Compounds

Also Published As

Publication number Publication date
EP0995436A3 (de) 2003-11-05
CA2177739A1 (fr) 1995-06-15
JPH09508893A (ja) 1997-09-09
WO1995015948A1 (fr) 1995-06-15
EP0734379B1 (de) 2001-03-07
US6013656A (en) 2000-01-11
FR2713639A1 (fr) 1995-06-16
US5849760A (en) 1998-12-15
EP0734379A1 (de) 1996-10-02
EP0995436A2 (de) 2000-04-26
JP3594310B2 (ja) 2004-11-24
AU1245495A (en) 1995-06-27
FR2713639B1 (fr) 1996-08-30
ES2157315T3 (es) 2001-08-16
DE69426835D1 (de) 2001-04-12

Similar Documents

Publication Publication Date Title
DE69426835T2 (de) Derivate von 2-arylalkenyl-azacyclo alkan als sigma rezeptor-liganden, verfahren zu ihrer herstellung und ihrer therapeutischer anwendung
DE69304587D1 (de) Poröser Film, Verfahren zu seiner Herstellung und Anwendung
DE69820552D1 (de) 4,4-Dihydroxypyrazolin-5-on-Derivate, Verfahren zu deren Herstellung und Verwendung als Kosmetika
DE69737009D1 (de) Polymerisierter Toner und Verfahren zu dessen Herstellung
DE69130221T2 (de) Oligosaccharidoxazolines, konjugate von oligosacchariden und verfahren zu ihrer herstellung
DE69603829D1 (de) Schalwandler und verfahren zu dessen herstellung
DE69703993T2 (de) Einbügelbarer Einlagestoff und Verfahren zu dessen Herstellung
DE4498692T1 (de) Pharmazeutische Kompositionen zum Vorbeugen und Heilen von Krebserkrankungen und Verfahren zu ihrer Herstellung
DE58905246D1 (de) Heterocyclische substituierte alkoxycumarine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel.
DE69739222D1 (de) Kapseltoner und verfahren zu dessen herstellung
DE69625176D1 (de) Camptothecin-derivate und verfahren zu ihrer herstellung
DE69333396D1 (de) Einschlusskomplex von Taxol, Verfahren zu seiner Herstellung und Verwendung
DE59604829D1 (de) Kontinuierliches Verfahren zur Herstellung von 4-Amino-2,2,6,6-tetramethylpiperidin
DE69417527D1 (de) Verfahren zu Herstellung von alfa-Tocoferol Derivaten
DE69111327D1 (de) Block von Mikroverbindungsstiften und Verfahren zu dessen Herstellung.
DE69522642T2 (de) Hymenialdisin und seine derivate, verfahren zur herstellung von zwischenprodukten zu ihrer synthese und besagte zwischenprodukte
DE69713040D1 (de) Verfahren zur Herstellung von Cyclopropylacetylen und dessen Derivaten
DE59506347D1 (de) Zirkondioxidpulver, Verfahren zu seiner Herstellung und Verwendung
DE59600661D1 (de) Verfahren zur Herstellung von d,I-Menthol
DE59607664D1 (de) Verfahren zur Herstellung von 2,4,4,7-Tetramethyl-oct-6-en-3-on und dessen Verwendung als Riechstoff
DE69625174T2 (de) Gleitteil und verfahren zu dessen herstellung
DE69622024T2 (de) Phosphorylierte derivate von nitronen, verfahren zu ihrer herstellung und sie enthaltende zusammensetzungen
DE59209489D1 (de) Verwendung von 1-Thiocarbamoyl 5-hydroxy-pyrazolen als Mikrobizide, 1-Thiocarbamoyl 5-hydroxy-pyrazole und Verfahren zu ihrer Herstellung
DE59510416D1 (de) Verfahren zur Herstellung von Chlormethylpyridin Derivaten und Acylaminomethylpyridine als Zwischenprodukte
ATE259777T1 (de) Benzylaminderivate und phenylethylaminderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: PFIZER HOLDING FRANCE, PARIS, FR

8339 Ceased/non-payment of the annual fee